Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Multiple Sclerosis (RMS)”

88 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 88 results

Large-scale testing (Phase 3)Study completedNCT03277261
What this trial is testing

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
TG Therapeutics, Inc. 549
Not applicableStudy completedNCT01141751
What this trial is testing

An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 334
Post-approval studies (Phase 4)Study completedNCT01895335
What this trial is testing

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

Who this might be right for
Multiple Sclerosis
Sanofi 1,001
Testing effectiveness (Phase 2)Looking for participantsNCT07161258
What this trial is testing

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
Hoffmann-La Roche 12
Post-approval studies (Phase 4)Study completedNCT03257358
What this trial is testing

Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 382
Large-scale testing (Phase 3)Study completedNCT00958009
What this trial is testing

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

Who this might be right for
Multiple Sclerosis
EMD Serono 109
Large-scale testing (Phase 3)Study completedNCT04353492
What this trial is testing

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 562
Large-scale testing (Phase 3)Ended earlyNCT04032171
What this trial is testing

Study of Evobrutinib in Participants With RMS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc. 1
Large-scale testing (Phase 3)Active Not RecruitingNCT04586023
What this trial is testing

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
Hoffmann-La Roche 751
Not applicableLooking for participantsNCT06486779
What this trial is testing

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals 160
Testing effectiveness (Phase 2)WithdrawnNCT04079088
What this trial is testing

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
Biogen
Post-approval studies (Phase 4)Study completedNCT05199571
What this trial is testing

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 99
Post-approval studies (Phase 4)Study completedNCT03784898
What this trial is testing

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Who this might be right for
Multiple Sclerosis
Genzyme, a Sanofi Company 13
Large-scale testing (Phase 3)Study completedNCT00735007
What this trial is testing

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis
EMD Serono 106
Post-approval studies (Phase 4)WithdrawnNCT02234869
What this trial is testing

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

Who this might be right for
Relapsing Multiple Sclerosis
Biogen
Not applicableLooking for participantsNCT06515782
What this trial is testing

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

Who this might be right for
Multiple Sclerosis
University of Southern California 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05119569
What this trial is testing

Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis
Hoffmann-La Roche 109
Large-scale testing (Phase 3)Study completedNCT03277248
What this trial is testing

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
TG Therapeutics, Inc. 545
Large-scale testing (Phase 3)Study completedNCT02294058
What this trial is testing

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
Celgene 1,346
Not applicableNot Yet RecruitingNCT06887426
What this trial is testing

Cladribine Tablets as an Exit Therapy Strategy

Who this might be right for
Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University Hospital, Strasbourg, France 450
Load More Results